NO20030034L - En kombinasjon av FBPase-inhibitorer og antidiabetiske midler anvendbare for behandling av diabetes - Google Patents

En kombinasjon av FBPase-inhibitorer og antidiabetiske midler anvendbare for behandling av diabetes

Info

Publication number
NO20030034L
NO20030034L NO20030034A NO20030034A NO20030034L NO 20030034 L NO20030034 L NO 20030034L NO 20030034 A NO20030034 A NO 20030034A NO 20030034 A NO20030034 A NO 20030034A NO 20030034 L NO20030034 L NO 20030034L
Authority
NO
Norway
Prior art keywords
diabetes
treatment
combination
agents useful
antidiabetic agents
Prior art date
Application number
NO20030034A
Other languages
English (en)
Other versions
NO20030034D0 (no
Inventor
Paul D Van Poelje
Mark D Erion
Toshihiko Fujiwara
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO20030034D0 publication Critical patent/NO20030034D0/no
Publication of NO20030034L publication Critical patent/NO20030034L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20030034A 2000-07-06 2003-01-03 En kombinasjon av FBPase-inhibitorer og antidiabetiske midler anvendbare for behandling av diabetes NO20030034L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21653100P 2000-07-06 2000-07-06
PCT/US2001/021557 WO2002003978A2 (en) 2000-07-06 2001-07-05 A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES

Publications (2)

Publication Number Publication Date
NO20030034D0 NO20030034D0 (no) 2003-01-03
NO20030034L true NO20030034L (no) 2003-03-05

Family

ID=22807416

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030034A NO20030034L (no) 2000-07-06 2003-01-03 En kombinasjon av FBPase-inhibitorer og antidiabetiske midler anvendbare for behandling av diabetes

Country Status (18)

Country Link
EP (1) EP1372660A2 (no)
JP (1) JP2004508297A (no)
KR (1) KR100854851B1 (no)
CN (2) CN100396283C (no)
AU (2) AU2001273271B2 (no)
BR (1) BR0112212A (no)
CA (1) CA2412142A1 (no)
CZ (1) CZ20035A3 (no)
HU (1) HUP0301830A3 (no)
IL (2) IL153513A0 (no)
MX (1) MXPA02012713A (no)
NO (1) NO20030034L (no)
NZ (1) NZ523227A (no)
PL (1) PL365779A1 (no)
RU (1) RU2328308C2 (no)
SK (1) SK62003A3 (no)
WO (1) WO2002003978A2 (no)
ZA (1) ZA200300044B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
JP2002524463A (ja) 1998-09-09 2002-08-06 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規な芳香族インヒビター
AU2001245532B2 (en) 2000-03-08 2005-08-11 Metabasis Therapeutics, Inc. Novel aryl fructose-1,6-bisphosphatase inhibitors
NZ532427A (en) 2001-09-24 2008-07-31 Imp Innovations Ltd Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y)
AU2003201998C1 (en) 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EA013249B1 (ru) 2003-12-26 2010-04-30 Киова Хакко Кирин Ко., Лтд. Производные тиазола
US20070225259A1 (en) * 2004-08-18 2007-09-27 Qun Dang Novel Thiazole Inhibitors of Fructose 1,6-Bishosphatase
TW200633720A (en) * 2004-12-13 2006-10-01 Sankyo Co Medicinal composition for diabetic
TW200738245A (en) * 2005-08-22 2007-10-16 Sankyo Co Pharmaceutical composition containing FBPase inhibitor
WO2007129522A1 (ja) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited 乾式製造法製剤
US20100222304A1 (en) 2006-11-02 2010-09-02 Lillian W Chiang Methods of Treating Neuropathic Pain by Modulation of Glycogenolysis or Glycolysis
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
UY35065A (es) * 2012-10-08 2014-05-30 Lg Life Sciences Ltd Fármaco combinado que comprende gemigliptina y metformina y método para su preparación
CN104788350A (zh) * 2014-01-22 2015-07-22 天津大学 一种通过快速冷却结晶法获得甲糖宁药用优势晶型的方法
CN106831437B (zh) * 2016-02-03 2019-06-21 华中师范大学 含硝基乙烯基的酯类化合物及其制备方法和应用
CN114907285B (zh) * 2021-02-10 2023-09-22 华中师范大学 酰化糖精类化合物及其制备方法和应用、降血糖药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2008325A1 (en) * 1989-01-24 1990-07-24 Harry E. Gruber Method and compounds for aica riboside delivery and for lowering blood glucose
AU6452098A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
PT970095E (pt) * 1997-03-07 2004-03-31 Metabasis Therapeutics Inc Novos inibidores benzimidazole de frutose-1,6-bisfosfatase
AU6691798A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
AU3087099A (en) * 1998-03-16 1999-10-11 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase)
JP2002524463A (ja) * 1998-09-09 2002-08-06 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規な芳香族インヒビター
CN101164618A (zh) * 1998-12-24 2008-04-23 症变治疗公司 治疗糖尿病的fbp酶抑制剂与胰岛素致敏剂的组合
PT1248604E (pt) * 2000-01-21 2007-01-31 Novartis Ag Associações compreendendo inibidor de dipeptidilpeptidase-iv
GB0015627D0 (en) * 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses

Also Published As

Publication number Publication date
CN100396283C (zh) 2008-06-25
CN1599612A (zh) 2005-03-23
HUP0301830A2 (hu) 2003-11-28
CA2412142A1 (en) 2002-01-17
BR0112212A (pt) 2003-12-30
IL153513A0 (en) 2003-07-06
NO20030034D0 (no) 2003-01-03
ZA200300044B (en) 2004-05-06
KR20030031952A (ko) 2003-04-23
RU2328308C2 (ru) 2008-07-10
AU7327101A (en) 2002-01-21
CZ20035A3 (cs) 2003-05-14
PL365779A1 (en) 2005-01-10
WO2002003978A2 (en) 2002-01-17
WO2002003978A3 (en) 2003-10-16
NZ523227A (en) 2005-04-29
AU2001273271B2 (en) 2006-01-05
JP2004508297A (ja) 2004-03-18
SK62003A3 (en) 2003-09-11
HUP0301830A3 (en) 2007-10-29
EP1372660A2 (en) 2004-01-02
IL153513A (en) 2014-07-31
MXPA02012713A (es) 2004-09-10
KR100854851B1 (ko) 2008-08-27
CN101301294A (zh) 2008-11-12

Similar Documents

Publication Publication Date Title
NO20030034D0 (no) En kombinasjon av FBPase inhibitorer og antidiabetiske midler anvendbare for behandling av diabetes
NO20042147L (no) Heterocykliske forbindelser og fremgangsmater for anvendelse derav
NO20032668D0 (no) Gyraseinhibitorer og anvendelser derav
NO20022656L (no) Caspaseinhibitorer og anvendelse derav
CY2008010I1 (el) Ενωσεις που περιλαμβανουν αναστολεις διπεπτυδυλοπεπτιδασης-iv και αντιδιαβητικους παραγοντες
NO20020343L (no) Kaspase-inhibitorer og anvendelse derav
NO20042229L (no) Type 4-fosfodiestemseinhibitorer og anvendelse derav
NO20016314D0 (no) Blandinger og fremgangsmåte for oljefeltapplikasjoner
DK1251848T3 (da) Gyraseinhibitorer og anvendelse deraf
NO20011114D0 (no) FremgangsmÕte og anordning for brudd-/gruspakker
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
NO20022086D0 (no) Antidiabetisk formulering og fremgangsmåte
DK1339292T3 (da) Sammensætning og fremgangsmåde
PL374598A1 (en) Caspase inhibitors and uses thereof
EP1448218A4 (en) BETA SECRETASE INHIBITORS AND METHODS OF USE
AU2002361861A8 (en) Selective 11beta-hsd inhibitors and methods for use thereof
DK1322597T3 (da) Fremgangsmåde og intermediære
EP1337255A4 (en) USE OF P38 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY COUGH
AU2003232848A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
GB0003254D0 (en) Heterocyclic compounds and their therapeutic use
IS7275A (is) Samsetning fyrir hollegg og notkun á henni
DE60106740D1 (de) Hydrazid und alkoxyamid angiogeneseinhibitoren
IL158395A0 (en) Aromatase inhibitor for use in reproduction
NO20032821D0 (no) Sea-trosy og beslektede fremgangsmåter
NO20026065L (no) Prosesser for måling av dinofysistoksin og av yessotoksin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application